Celgene’s most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $89.00 short put and a strike $84.00 long put offers a potential 36.61% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $89.00 by expiration. The full premium credit of $1.34 would be kept by the premium seller. The risk of $3.66 would be incurred if the stock dropped below the $84.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 56.24 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Wait for a Pullback Before Rolling the Dice on SPPI Stock
Fri, 13 Apr 2018 01:00:48 +0000
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) again finds itself in the news after a successful drug trial. Spectrum is engaged in drug development, licensing agreements and work with other pharma companies. Its six currently approved drugs fight diseases such as cancer.
U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report
Thu, 12 Apr 2018 21:51:00 +0000
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn’t happen and Booker’s new analysis hammers those drug companies.
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation
Thu, 12 Apr 2018 18:49:00 +0000
The Klein Law Firm announces the commencement of an investigation of Celgene Corporation concerning possible violations of federal securities laws.
Otezla: Shoring Up Celgene’s Top Line
Thu, 12 Apr 2018 17:20:06 +0000
Celgene Corporation (CELG) is an integrated global biopharmaceutical company focused on innovative therapies for treating cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation. Celgene’s Otezla is an oral small molecule inhibitor of PDE4. Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in the United States, Japan, the European Union, and other international markets.
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Thu, 12 Apr 2018 10:00:00 +0000
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Celgene Corporation securities during the period between September 12, 2016 and February 27, 2018, inclusive .
Also on Market Tamer…
Follow Us on Facebook